Embed Size (px)
Citation preview
CURRICULUM VITAE
***
Dr. M. A. RAJA
Updated November 2011
Name Madras Ananthanarayanan RAJA
Permanent Address No 13 (old 52) “Anand”
V Block, 12th Street,
Anna Nagar, Chennai,
India. PIN: 600 040
Present Address Same
Telephone : Work 00 9144 33151128 Home 00 9144 26214486
Facsimile : Work 00 9144 24363646
e-mail: [email protected]
Date of Birth 10 - 6 - 1954
Gender Male
Marital Status Married with two children
Nationality Indian / British Resident
Medical Registration UK : 3404140 (Specialist Registration eligible)
India : 30121
Qualifications ESMO Medical Oncology Certificate Examination
- November 1996
MRCP United Kingdom
- June 1988
PLAB Exam United Kngdom
- April 1984
MD General Medicine, Madras India
- October 1982
Member of National Academy of Medical Sciences India
- July 1980
MBBS, Madras University India
- December 1976
General Education Don Bosco Matriculation School
Recipient of Gold Medal - Best Outgoing Student
Current Position SENIOR CONSULTANT in MEDICAL ONCOLOGY
Apollo Speciality Hospital,Chennai, India
June 2004 – Till Date
Responsibilities include management of cancer patients in in-
patient and out-patient settings, participation in academic
activities – tumour board, symposia, conferences, and teaching
of medical students, postgraduate studetns, nursing, and other
paramedical staff.
Apollo Speciality Hospital, Chennai is part of the Apollo
Group of hospitals, declared as “Centre of Excellence” by
Government of India, and considered the best private sector
hospital in India by independent surveys. It hasalso recently
been accredited by the JCIA (USA). The Speciality hospital is
an offshoot of the parent hospital, also in Chennai, and
between the two, offer care to patients in over 60 departments,
in out-patient as well as in-patient settings. It is among the
earliest hospitals to perform cord blood transplant, liver
transplant, and there is a full fledged bone marrow transplant
unit with a team of oncologists, and specialised nursing staff.
Access to facilities include PET-CT Scan, Spiral CT, Linear
Accelerators, State-of-the-art Telecobalt Unit , Simulator,
Treatment Planning System, Medium Dose Selection
Brachytherapy Unit, Bone Marrow Transplantation Unit,
Transrectal/vaginal Ultrasound, full fledged laboratory also
offering immunochemistry, tumour markers, surgical
oncologyservices in cluding laparoscopic surgery, and
Teleradiotherapy planning network
Previous Position
July 2004 – June 2012 ASSOCIATE PROFESSOR, ONCOLOGY
Senior Consultant, Oncology
Sri Ramachandra Medical College, Chennai, India
Sri Ramachandra Medical College & Research Institute is a
Deemed University, an autonomous body primarily dedicated
to the purposes of medical education, research and health care.
Sri Ramachandra Hospital is a 1050 bedded teaching hospital
which was commissioned in the month of Jan. 1988. In
addition to the free teaching beds, 300 additional private beds
also available, which are utilised by all the specialities and
particularly the advanced speciality services like Cardiology,
Cardio Thoracic Surgery, Neurology, Neuro Surgery,
Nephrology, Oncology, Transplant services and Advanced
Trauma Orthopaedic services. The general wards cater to the
needs of thousands of villagers from several hundred villages
in the neighbourhood. Sri Ramachandra Hospital has well knit
diagnostic services supervised by specialists in the field. The
clinical laboratory with all the departments like Clinical
Chemistry, Hematology, Clinical Pathology and Microbiology
is located in a comprehensive set up with a complete array of
semi-automatic and automatic analysers. This is being
constantly upgraded to meet the needs of our consultants. In
terms of Radiology and imaging science, the hospital has five
800 MA x-ray machines, one of which is dedicated for
fluoroscopy, 4 ultra sound machines, a mammogram unit, a
CT Scan, MRI and Nuclear Gamma Camera. This division can
perform invasive DSA Angio Studies utilising Cath lab and C
- Arm facilities. The other diagnostic facilities like Pulmonary
testing, EEG, EMG, Echocardiography, Treadmill, colour
doppler etc., are located in the respective departments. Sri
Ramachandra Medical College & Research Institution is a
charitable private trust undergraduate & post-graduate
institution in the suburbs of Madras city (Chennai) in South
India. The medical college has a Deemed University status. It
is situated on a sprawling one hundred and seventy four acres
(about 75 million square feet) campus. Besides the medical
college the campus houses many other colleges and runs
various medical and nursing courses.
Other Appointments
August 1992 – April 2004 MEDICAL ONCOLOGIST King Faisal Specialist Hospital & Research Centre
Section of Medical Oncology
The Department is the biggest Tertiary Referral Centre for
Oncology for the entire Kingdom of Saudi Arabia and the
Middle East.
Responsibilities include :
Running Out-patient Clinics
Management of In-patients
Providing Consultation services to other departments
Participation in Phase II/III Local / International Trials
Presenting Abstracts / Publications
Teaching Medical Residents and Nursing Staff
I have actively participated in the in-service lectures for nursing staff, and teaching of Medical
Residents.
I have helped to draw up standardisation for chemotherapy regimes, done the work-up for
peripheral stem cell transplant, management of emergencies like hypercalcemia, febrile neutropenia
etc.
I have written a nurses guide to peripheral stem cell transplant.
I draw up the section staff assignments / responsibilities on a weekly basis, and also organise the
on-call rota for the section.
I have taken active part in the presentation of Grand Rounds, cases in Tumour Board, Journal
club, other teaching sessions.
UK Appointments :
June 1990 - July 1992 HON. SENIOR REGISTRAR, MEDICAL ONCOLOGY
IMPERIAL CANCER RESEARCH FUND FELLOW The Royal London Hospital, London E1
Dr R T D Oliver
Sir Maxwell Joseph Professor in Medical Oncology
Dr. C. Gallagher
Senior lecturer, Medical Oncology
Out- and In-patient care of all cancer patients. The
department has a particular interest in genito-urinary
and hormone dependant malignancies, and biologic
treatment of cancer, besides conventional
chemotherapy
Clinical Research with participation in running various
trials including departmental, collaboration with
multicentric trials organized by the Medical Research
Council, East Anglian Oncology Group, Imperial
Cancer Research Fund among others
Teaching of Medical Students and Nurses
Other Appointments in the UK :
August 1988 - June 1990 REGISTRAR, GENERAL MEDICINE Rotational Training Scheme
Dudley Health Authority
Dr A M Zalin Endocrinology / Diabetes Mellitus
Dr C W F Clarke
Dr B J M Jones Gastroenterology
Dr A N Hamlyn
Dr M F Bone Respiratory Medicine
Dr J M Cushley
Dr J Flint Cardiology
Dr N H Stentiford
Dr D D Hilton Nephrology
Dr S Smith
Dr S G N Richardson Hematology / Oncology
Dr S El Tamtamy
Dr J P Delamere Rheumatology
Dr P J Ashurst Dermatology
Two year rotational appointment with six months at Corbett
Hospital, twelve months at Russells Hall Hospital with limited
commitments at Guest / Burton Road Hospitals
February 1988 - July 1988 SENIOR HOUSE OFFICER,
ONCOLOGY AND RADIOTHERAPY Western Infirmary, Glasgow
Professor S B Kaye
Professor A Barrett
February 1986 - January 1988 SENIOR HOUSE OFFICER, GENERAL MEDICINE Rotational Scheme
Dudley Health Authority
18 months in acute general medicine working with different
consultants with special interests :
Dr N H Stentiford Cardiology/CCU
Dr C W F Clarke Endocrinology
Dr S G N Richardson Hematology
Dr B J M Jones / Dr A N Hamlyn Gastroenterology
Dr D D Hilton Nephrology
Dr P J Ashurst Dermatology
6 months in Medicine for Elderly with
Dr W A Saunders, Dr L Hume, Dr H Irfan
February 1985 - January 1986 SENIOR HOUSE OFFICER, GERIATRIC MEDICINE New Cross Hospital, Wolverhampton
Dr E M Tilsen, Consultant Geriatrician
June 1984 - January 1985 LOCUM SENIOR HOUSE OFFICER, MEDICINE
Frenchay Hospital, Bristol
Dr C Burns-Cox
Orpington Hospital, Kent
Dr P Crome
Farnborough Hospital, Kent
Dr Saunders
Ysbyty Gwynedd, Wales
Dr H Owen
Previous Appointments in India :
January 1982 - February 1984 REGISTRAR, MEDICINE / ONCOLOGY Cancer Institute, Madras
Dr K Shantha, Director and Head of Medical Oncology
June 1979 - June 1981 MD POST-GRADUATE RESIDENT Kilpauk Medical College Hospital, Madras
September 1978 - February 1979 SENIOR HOUSE OFFICER, GENERAL MEDICINE Government General Hospital, Madras
Dr A M Selvaraj, Consultant Physician
January 1978 - July 1978 SENIOR HOUSE OFFICER, CHEST MEDICINE Government Chest Institute, Madras
Dr K V Krishnaswamy, Director
January 1977 - December 1977 PRE-REGISTRATION HOUSE OFFICER Kilpauk Medical College Hospital and Government
Royapettah Hospitals, Madras
WORK EXPERIENCE Thirty three years post qualification
Nine years in UK, thirteen in India, and eleven in Saudi
Arabia
Twenty four years in Oncology
Employment in peripheral / central / tertiary hospitals
Training in most Medical sub-specialties
Independent management of out- and in-patient services
Experience in Emergency Medicine, Intensive / Coronary Care
PRACTICAL PROCEDURES Independent Bronchoscopies in excess of 200
Temporary Cardiac pacemaker insertion
Peritoneal Dialysis
Insertion of Central Venous Lines
Liver Biopsy
Pleural paracentesis and Biopsy
Lumbar Puncture
Bone Marrow Aspiration and Biopsy
ADMINISTRATION Drawing up leave schedules, on-call rota, daily schedule for
all staff in the department in current job
Junior Staff Representative for District 1988 - 1990
Member, Medical Division, 1988 - 1990
Pre-Registration House Officers Representative 1977 - 1978
College Union President, 1975 - 1976
TEACHING EXPERIENCE Teaching under graduates, medical residents,
MRCP candidates,
Nurses, other para medical staff
REFEREES :
Dr R T D Oliver
Sir Maxwell Joseph Professor of Clinical Oncology
Royal London and St. Bartholomew's Hospital
Colston Ward, 1st Floor
King George V Building
West Smithfield, London
United Kingdom.
EC1A 7BE
Tel : 0171 601 7820
Fax : 0171 601 7577
Dr A Barrett
Professor and Director
Beatson Oncology Centre
Western Infirmary
Glasgow, Scotland
United Kingdom.
G11 6NT
Tel : 0141 211 2123
Fax : 0141 211 6356
Dr S G N Richardson
Consultant Hematologist
Russells Hall Hospital
Dudley, West Midlands
United Kingdom.
DY1
Protocols :
1. Wierzbicki R, Ezzat A, El-Warith A, Raja M A, Khalifa, Fadda M, Cronstedt J, Amin T :
Approved CPC. Phase II Study of Oral Medroxyprogesterone Acetate in Hepatocellular Carcinoma.
Approved via CPC Form B.
2. Wierzbicki R, Ezzat A, El-Warith A, Raja M A, Khalifa F, Antonius J, Moreau P, Younge D,
Lindahl S, Al-Sudairy S : Phase II Study of Oral VP-16 in Relapsed Osteogenic Sarcoma. Approved
via CPC Form B.
3. Bazarbashi S, Wierzbicki R, Amin T, Dalmark M, El-Warith A, Khalifa F, Raja M A : Phase II
Trial of 5 FU and Leucovorin in the Treatment of Inoperable or Metastatic Gall Bladder and Bile
Duct Cancer. Approved CPC #92-94, 12 September 1992.
4. Wierzbicki R, Ezzat A, Bazarbashi S, El-Warith A, Khalifa F, Raja M A : International Trial to
evaluate the effect of subcutaneous Erythropoietin in patients with Anaemia secondary to
Chemotherapy. Approved CPC #92-93, 7 November 1992.
5. Wierzbicki R, Ezzat A, Bazarbashi S, Berry J, El-Warith A, Khalifa F, Raja M A : Randomised
Phase II study comparing Adriamycin vs two schedules of High Dose Epirubicin in Advanced Soft
Tissue Sarcoma (KFSH Sarcoma working group / EORTC Protocol #62901). Approved CPC #92-
98, 7 November 1992.
6. Wierzbicki R, Ezzat A, Bazarbashi S, Berry J, El-Warith A, Khalifa F, Raja M A : Randomised
Phase II study comparing two different Ifosfamide dose regimens and Treatment of Metastatic Soft
Tissue Sarcoma (KFSH Sarcoma working group / EORTC Protocol #62912). Approved CPC #92-
98, 7 November 1993.
7. Bazarbashi S, Dalmark M, El-Warith A, Ezzat A, Khalifa F, Raja M A, Wierzbicki R : Phase II
Trial of 5 FU, Cisplatin, and Recombinant Human Interferon Alpha 2B as First line Treatment of
Advanced Urothelial Cancer. Approved CPC #92-95, March 1993.
8. Wierzbicki R, Bazarbashi S, Dalmark M, El-Warith A, Ezzat A, Khalifa F, Raja M A :
Randomised study comparing conventional dose Doxorubicin, Ifosfamide vs High dose
Doxorubicin, Ifosfamide, GMCSF in the treatment of Advanced Soft Tissue Sarcoma in adults.
Approved CPC #93-106, April 1993.
9. Ezzat A, Wierzbicki R, Bazarbashi S, Dalmark M, Berry J, El-Warith A, Khalifa F, Raja M A :
EORTC Protocol #10901 : Post operative Adjuvant Chemotherapy followed by Adjuvant
Tamoxifen vs Nil for patients with Operable Breast Cancer. Approved CPC #93-107, 26 June 1993.
10. Ezzat A, Wierzbicki R, Bazarbashi S, Dalmark M, Berry J, El-Warith A, Khalifa F, Raja M A :
EORTC Protocol #10902 : Pre operative Chemotherapy in Operable Breast Cancer. Approved CPC
#93-108, 26 June 1993.
11. Wierzbicki R, Ezzat A, Bazarbashi S, Dalmark M, Berry J, El-Warith A, Khalifa F, Raja M A :
Randomised trial of Chemotherapy with or without GCSF in Operable Osteosarcoma. Approved
CPC #93-111, 26 June 1993.
12. Bazarbashi S, El-Warith A, Berry J, Dalmark M, Ezzat A, Khalifa F, Raja M A, Wierzbicki R :
Phase II study of alternating two Chemotherapy regimes in the Salvage Treatment of Refractory or
Relapsed Hodgkin's Disease. Approved CPC #93-115, 1 November 1993.
13. Bazarbashi S, Amin T, Berry J, Cronstedt J, Dalmark M, El-Warith A, Ezzat A, Fadda M,
Khalifa F, Raja M A, Rostom A, Wierzbicki R : Phase II study of 5 FU, Cisplatin, and
Recombinant Human Interferon Alpha 2B in the Treatment of Advanced Oesophageal Cancer.
Approved CPC #93-117, 11 October 1993.
14. Bazarbashi S, Berry J, Dalmark M, El-Warith A, Ezzat A, Khalifa, Raja M A, Rostom A,
Wierzbicki R : Phase III study to compare COPP/ABVD Standard Chemotherapy regimen with
Dose / Time intensified with GMCSF (SCH 39-3000, Sandoz-Schering Plough) in Hodgkin's
Disease Stages III and IV. Approved CPC #93-122, 24 October 1993.
15. Ezzat A, Berry J, Bazarbashi S, El-Warith A, Khalifa F, Raja M A, Al-Sudairy S, El-Yazigi A :
Tamoxifen combined with Cytotoxic Chemotherapy in patients with Non Hodgkin's Lymphoma.
Approved CPC #93-120, 20 December 1993.
16. Berry J, Ezzat A, El-Warith A, Khalifa F, Raja M A, El-Yazigi A : Pharmacokinetic study of
Etoposide in elderly patients with Non Hodgkin's Lymphoma. Approved CPC #94-132, 9 March
1994.
17. Berry J, Ezzat A, El-Warith A, Khalifa F, Raja M A, El-Yazigi A : Phase II trial of Taxol and
Cisplatin in patients with Metastatic Breast Cancer. Approved CPC #94-135, 9 March 1994.
18. Wierzbicki R, El-Warith A, Antonius J, Bazarbashi S, Berry J, Dalmark M, Ezzat A, Khalifa F,
Lindahl S, Moreau P, Raja M A, Younge D : Phase II study of daily oral Etoposide as second line
Treatment in Advanced Soft Tissue Sarcoma, EORTC Protocol #62932. Approved CPC #94-136, 9
March 1994.
19. Wierzbicki R, El-Warith A, Antonius J, Bazarbashi S, Ezzat A, Gray A, Khalifa F, Lindahl S,
Moreau P, Raja M A, Younge D : Randomised trial of Adjuvant Chemotherapy with High dose
Doxorubicin, Ifosfamide and GMCSF in High Grade Soft Tissue Sarcoma, EORTC #62931.
Approved CPC 12 April 1994.
20. Wierzbicki R, Antonius J, Bazarbashi S, Berry J, Dalmark M, Ezzat A, Gray A, Kadhi S,
Khalifa F, Lindahl S, Moreau P, Raja M A, El-Warith A, Younge D : Randomised study for
treatment of Ewing's Sarcoma of Bone. Approved CPC #93-127, 15 March 1994.
21. Bazarbashi S, Berry J, El-Warith A, Ezzat A, Kardar A, Khalifa F, Khudair W, Mansi M,
Peterson B, Raja M A, Sundin T : Phase II study of alternating intravesical Interferon Alpha 2B and
BCG in the Treatment and Prevention of Recurrent Superficial Bladder Cancer. Approved CPC
#94-142, 15 June 1994.
22. Berry J Ezzat A, Raja M A, El-Warith A : Feasibility study comparing Taxol / Cisplatin with
standard 5 FU, Adriamycin, Cytoxan as Neo-adjuvant Therapy of Breast Cancer. Approved CPC
#95-161, 21 November 1995.
23. Berry J, Ezzat A, Raja M A, El-Warith A, Rahal M : Phase II study of Ifosfamide / Cisplatin in
Metastatic Breast Cancer. Approved CPC 951-101.
24. Bazarbashi S, Ezzat A, Raja M A, El-Warith A : Phase II trial of 5 FU, Cisplatin, and Alpha
Interferon as first line Treatment of Advanced Urothelial Cancer. Approved CPC #92-95.
25. Bazarbashi S, Rostom A, El-Warith A, Ezzat A, Kandil A, Raja M A, Rahal M : Phase II trial
of Combined Modality Treatments with Chemotherapy and Radiotherapy for Stage I and II
Hodgkin's Disease. Approved CPC #951-002, 8 July 1996.
26. Ezzat A, Rahal M, Ranginwala M, Raja M A, Ajarim D, Bazarbashi S : International
multicentre Phase II trial of Docetaxel in combination with Doxorubicin or Docetaxel and
Doxorubicin given sequentially as first line chemotherapy for metastatic breast cancer.
27. Bazarbashi S, Amin T, Ezzat A, Pai C, Ajarim D, Raja M A, Rahal M, Memon M, Ranginwala
M, El-Foudeh M : Phase II Trial of Neo-Adjuvant and Adjuvant Chemotherapy in Operable
Epidermoid Oesophageal Cancer (RAC 981021).
28. Bazarbashi S, Ezzat A, Ajarim D, Ranginwala M, Memon M, Raja M A, Pai C, Rahal M, El-
Foudeh M : Phase II Open Label, Non Therapy, Probe Study of Caelyx in Hepatocellular
Carcinoma.
29. Ezzat A, Rahal M, Stuart R, Ajarim D, Ranginwala M, Raja M A, Pai C, El-Foudeh M, Rostom
A, Sorbris R : Phase II Study of Neo-Adjuvant Intensive Sequential Chemotherapy with
Adriamycin, Taxol, and Cisplatin in the treatment of Locally Advanced Breast Cancer.
30. Ajarim D, Stuart R, Ezzat A, Bazarbashi S, Mann B, Ibrahim E, Rahal M, El Foudeh M, Pai C,
Raja M A, Hussain S : Phase II single arm study of Gemcitabine in combination with Cisplatinum
in treatment of Recurrent or Metastatic Breast Cancer.
31. Bazarbashi S, Raja M A, Kattan S : Phase II trial of concurrent administration of intravesical
BCG and interferon -2b in the treatment and prevention of recurrence of superficial transitional
cell carcinoma of the urinary bladder.
32. Bazarbashi S, Ajarim D, El Foudeh M, Ezzat A, Tweigieri T, Maghfoor I, Akhtar S, Al Sayed
A, Rahal M, Raja M A, Pai C, El Weshi A : Phase II study of gemcitabine, ifosfamide, etoposide
(GIE) combinaton in the treatment of relapsed or refractory Hodgkin’s disease and non-Hodgkin’s
lymphomas.
33. Al Sayed A, Ezzat A, Bazarbashi S, Tweigieri T, Ajarim A, Akhtar S, Maghfoor I, El Foudeh
M, Raja M A, Rahal M, Pai C, El Weshi A : A clinical evaluation of the effect of maintaining
haemoglobin levels with weekly EPREX (Epoetin alfa) in subjects with lymphoid malignancies
(Hodgkin’s disease, Non-Hodgkin’s lymphoma, Chronic Lymphocytic Leukemia and Multiple
Myeloma) undergoing therapy.
34. Bazarbashi S, Rehman K, Ajarim D, Memon M, Maghfoor I, Al Sayed A, Akhtar S, Ezzat A,
Raja M A, El Foudeh M, Pai C, Rahal M, El Weshi A : Multicentre Phase III randomised trial
comparing fortnightly Irinotecan plus infusion 5-Fluorouracil modulated by leucovorin (CPT11 +
DeGramont regimen) to monthly bolus 5-Fluorouracil modulated by Leucovorin (Mayo Clinic
regimen) as adjuvant chemotherapy in high risk Stage III (N2) Colon Cancer (RAC 2021-036).
35. Bazarbashi S, Rahal M, Isbister W, Rehman K, El Foudeh M, Pai C, El Weshi A, Raja M A,
Memon M, Sanea N, Al Jabbar A : A pilot trial of pre-operative radiotherapy using Capecitabine
and External Beam Radiation followed by definitive surgery in patients with localized non-
metastatic rectal cancer (RAC 2011031).
Publications :
1. Krishnaswami KV, Rahim M A, Parthasarathy R, Raja M A : BCG Test. Indian Journal of
Tuberculosis (1979) Vol XXVI, No 2, 70-74.
2. Oliver R T D, Ong J Y H, Raja M A : Secondary pre-leukemia and etoposide. Lancet (1991) Vol
338, 1269-1270.
3. Raja M A, Oliver R T D, Badenoch D, Blandy J P : Orchidopexy and transformation of
seminoma to non-seminoma. Lancet (1992) Vol 338, 930.
4. Oliver R T D, Raja M A : Rapid diagnosis of testicular tumour. Br J Hosp Med (1992) Vol 47
(4), 304.
5. Oliver R T D, Raja M A, Ong J Y H, Gallagher C J : Pilot study to evaluate impact of a policy of
adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I
cancer patients. J Urol (1992) Vol 148, 1453-1456.
6. Raja M A, Oliver R T D, Blomley M : Hurricane growth of malignant trophoblastic teratoma.
Postgrad Med J (1993) Vol 69, 473-474.
7. Ezzat A, Raja M A, Eisa A, Furayh O : Cryoglobulinemia ten years before onset of Lymphoma.
Acta Oncologica (1994) Vol 33 (1), 69-70.
8. Ezzat A, Abdulkareem M A, Raja M A, Te O B, Anderson M, Michels D K : Gastrointestinal
Non-Hodgkin's Lymphoma in adults at KFSH & RC (1985-1992). Annual Report of the Tumour
Registry (1993).
9. Ezzat A A, Khalifa F, Berry J, Khan B, Raja M A, Abdel-Warith A : E-SHAP : An effective
treatment in selected patients with relapsed non-Hodgkin's lymphoma. Annals of Oncology (1994)
Vol 5, 453-456.
10. Ezzat A, Raja M A, Akhtar M, Bazarbashi S, Tulbah A, Wierzbicki R : Ki-1 large cell
lymphoma : a clinical study of 12 cases. Annals of Saudi Medicine (1995) Vol 15 (1), 25-28.
11. Ezzat A, Raja M A, Te O B, Michels D K, Bazarbashi S : Frequency and distribution of 22,836
adult cancer cases referred to King Faisal Specialist Hospital and Research Centre. Annals of Saudi
Medicine (1996) Vol 16 (2), 152-158.
12. Ezzat A, Raja M A, Berry J, Zwaan F E, Jamshed A, Rhydderch D, Rostom A, Bazarbashi S :
Impact of Pregnancy on Non-Metastatic Breast Cancer : A Case Control Study. Clinical Oncology
(1996) Vol 8, 367-370.
13. Ezzat A, Siotus N, Raja M A, Ali A : Synchronous Hodgkin's Disease and Non-Hodgkin's
Lymphoma. Acta Oncologica (1996) Vol 35 (6), 755-757.
14. Ezzat A, Raja M A, Berry J, El-Warith A, Khan B, Rhydderch D : A Prospective study of
VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's Lymphoma. Am J Clin Oncol
(1997) Vol 20 (2), 179-183.
15. Ezzat A, Bazarbashi S, Radwi A, El-Warith A, Raja M A, Rahal M, Beleno J : Phase II Study
of Combination Carboplatin and Chronic Oral VP-16 in Pre-treated Metastatic Breast Cancer.
Turkish Journal of Cancer (1998) Vol 28 (1), 12 - 16.
16. Ezzat A, Raja M A, Berry J, Bazarbashi S, Zwaan F, Rahal M, El-Warith A : Phase II Trial of
Circadian-Timed Paclitaxel and Cisplatin in Metastatic Breast Cancer. Annals of Oncology (1997)
Vol 8: 663 - 667.
17. Ezzat A, Raja M A, Rostom A, Zwaan F, Akthar M, Bazarbashi S, Ingemansson S, Jamshed A
: An Overview of Breast Cancer. Annals of Saudi Medicine (1997) Vol 17 (1), 10 - 15.
18. Ezzat A, Raja M A, Zwaan F, Brigden M, Rustom A, Bazarbashi S : The lack of Age as a
significant prognostic factor in Non-Metastatic Breast Cancer. European Journal of Surgical
Oncology (1998) Vol 24 : 23 - 27.
19. Bazarbashi S, Khafaja Y, El-Warith A A, Manji M, Jamshid A, Raja M A, Ezzat A :
Epidermoid Carcinoma of Anal Canal - Treatment Results and Prognostic Variables. Annual Report
of the Saudi Tumour Registry 1997.
20. Ezzat A, Raja M A, Bakri Y, Zwaan F, Subhi J, Memon M, Schwartz P, Stuart R : Malignant
Ovarian Germ Cell Tumours - A Survival and Prognostic Analysis. Acta Oncologica (1999) Vol 38
(4), 455 - 460.
21. Ezzat A A, Ibrahim E M, Raja M A, Al-Subhi S, Rostom A, Stuart RK : Locally advanced
breast cancer in Saudi Arabia - high frequency of stage III in a young population. Medical Oncology
(1999) Vol 16, 95 - 103.
22. Shamash J, Oliver R T D, Ong J, Raja M A, Edmonds P, Gallagher C J, Ostrowski M J, LeVay
J, Willaims M : Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery
and ifosfamide-based chemotherapy. Annals of Oncology (1999) Vol 10, 685 – 692.
23. Ibrahim E M, Ezzat A A, Raja M A, Rahal M M, Ajarim D S, Mann B, Baloush A, Stuart R K,
Bazarbashi S : Primary gastric non-Hodgkin’s lymphoma – Clinical features, management, and
prognosis of 185 patients with diffuse large B-cell lymphoma. Annals of Oncology (1999) Vol 10,
1441 – 1449
24. Bazarbashi S, Raja M A, El Sayed A, Ezzat A, Ibrahim E, Kattan S, Kardar A, Peracha A,
Lindstedt E, Hanash K : Prospective Phase II trial of alternating intravesical Bacillus Calmette-
Guérin (BCG) and Interferon alpha IIB in the treatment and prevention of superficial transitional
cell carcinoma of the urinary bladder – Preliminary results. Journal of Surgical Oncology (2000)
Vol 74 (3), 181 – 184.
25. Ezzat A, Ibrahim E M, Ajarim D S, Rahal M M, Raja M A, Stuart R K, Tulbah A M, Kandil A,
Al-Malik O A, Bazarbashi S M : High complete pathological response in locally advanced breast
cancer using paclitaxel and cisplatin. Breast Cancer Research and Treatment (2000) Vol 62 : 237 –
244.
26. Bazarbashi S, Rahal M, Raja M A, El Weshi A, Pai C, Ezzat A, Ajarim A, Memon M, Al
Fadda M : A pilot trial of combination Cisplatin, 5-fluorouracil and interferon-α in the treatment of
advanced esophageal carcinoma. Chemotherapy (2002) 48 : 211 – 216.
27. Bazarbashi S, Pai C, Raja M A, Rahal M, Ezzat A, Hanash K : Phase II trial of cisplatin, 5-
fluorouracil and interferon-α-2B as first line treatment of advanced urothelial cancer. Urologic
Oncology (2003) 21(3) : 185-9.
28. El Weshi A, Memon M, Raja M. A., Bazarbashi S, Rahal M, El Foudeh M, Pai C, Allam A, El
Hassan I, Ezzat A: VIP (Etoposide, Ifosfamide, Cisplatin) in Adult Patients with Recurrent or
Refractory Ewing’s Sarcoma Family of Tumors. American Journal of Oncology (2004) 27(5) : 529-
34.
29. Ezzat A A, Ibrahim E M, Ajarim D S, Rahal M M, Raja M A, Tulbah A M, Al Malik O A, Al
Shabanah M, Sorbris R: Phase II study of neoadjuvant paclitaxel and cisplatin for operable and
locally advanced breast cancer: analysis of 126 patients. British Journal of Cancer (2004) 90(5) :
968 - 74.
30. Ibrahim E M, Ezzat A A, Rahal M M, Raja M A, Ajarim D S.Adjuvant chemotherapy in 780
patients with early breast cancer: 10-year data from Saudi Arabia. Medical Oncology 2005; 22(4) :
343-52
Abstracts / Oral Presentations / Posters :
1. Raja M A, Oliver R T D, Ong J, Gallagher C J : Weekly Cisplatinum in combination as salvage
for germ cell tumour patients failing standard 3 weekly platinum based regimes. British Association
for Cancer research / Association of Cancer Physicians / British Oncological Association Joint
Winter Meeting. Br J Cancer (1992) Vol 65, 974.
2. Raja M A, Ong J Y H, Oliver R T D : Randomised comparison of Cisplatin and Carboplatin in
combination for metastatic malignant teratoma. Seventh Scientific Meeting of British Oncological
Association / Nordic Cancer Societies. Proceedings July 1992.
3. Oliver R T D, Raja M A : Adjuvant chemotherapy for stage I malignant teratoma. American
Association for Cancer Research Meeting 1991.
4. Raja M A, Oliver R T D : Operation on undescended testes as a promoting factor for the
transformation of Seminoma to Malignant Teratoma. 3rd Copenhagen Workshop - Carcinoma in
situ and Cancer of the Testis, November 1992.
5. Wierzbicki R, Ezzat A, Bazarbashi S, Dalmark M, El-Warith A, Khalifa F, Raja M A, Moreau P,
Younge D, Kadhi S, Shah A, Sabbah R, Antonius J, Lindahl S : Phase II trial of chronic oral daily
VP-16 (etoposide) administration in Osteogenic Sarcoma. 29th Annual Meeting American Society
of Clinical Oncology (ASCO) (1993) Vol 12, 1651.
6. Ezzat A, Bakri Y, El-Senousi M, El-Warith A, Wierzbicki R, Dalmark M, Bazarbashi S, Dery JP,
Khalifa F, Raja M A, Newby W : Clinical study of Dysgerminoma. 29th Annual Meeting American
Society of Clinical Oncology (ASCO) (1993) Vol 12, 866.
7. Ezzat A, Raja M A, Bazarbashi S, El-Akkad S, Wierzbicki R, Dalmark M, El-Warith A, Khalifa
F : Ki-1 Large Cell Lymphoma - King Faisal Specialist Hospital & Research Centre 2 years
experience. Fifth International Conference on Malignant Lymphoma, Lugano, June 1993.
8. Wierzbicki R, Ezzat A, Bazarbashi S, Dalmark M, Abdel Warith A, Khalifa F, Raja M A, Amin
T, Fadda M, Ayoub A : Phase II study including Quality of Life Assessment of High Dose
Medroxyprogesterone Acetate in Unresectable Hepatocellular Carcinoma. Published Proceedings of
18th International Congress of Chemotherapy, Stockholm, June 1993.
9. Ezzat A, Raja M A, Wierzbicki R, Bazarbashi S, Khan B, Abdel Warith A, Khalifa F,
Rhydderch D : VEC-POB combination chemotherapy in intermediate/high grade non-Hodgkin's
Lymphoma - a prospective trial. Published in the 1994 Program/Proceedings of the American
Society of Clinical Oncology (ASCO) 30th Annual Meeting, May 1994.
10. Ezzat A, Khalifa F, Berry J, Khan B, Raja M A, Abdel Warith A : E-SHAP - an effective
treatment in selected patients with relapsed non-Hodgkin's Lymphoma. Published in the
Program/Proceedings of the American Society of Clinical Oncology (ASCO) 30th Annual Meeting,
May 1994.
11. Ezzat A, Khalifa F, Berry J, Wierzbicki R, Bazarbashi S, Abdel Warith A, Raja M A, Beleno J
: Phase II study of combination Carboplatin and chronic oral VP-16 in pre-treated metastatic breast
cancer. Published in the Program/Proceedings of the American Society of Clinical Oncology
(ASCO) 30th Annual Meeting, May 1994.
12. Wierzbicki R, Ezzat A, Bazarbashi S, El-Warith A, Khalifa F, Raja M A, McArthur P, Taibah
K, Abuzeid M, Mahasin Z, Otieschan A, Flores A : Phase II study of chronic oral daily
administration of VP-16 in advanced squamous cell carcinoma of head and neck. Saudi Oncology
Symposium, May 1994.
13. Bazarbashi S, Raja M A, Ezzat A, El-Warith A, Khalifa F : Single dose G-CSF avoids
chemotherapy delay in patients receiving conventional chemotherapy regimens for solid tumours.
The American Society of Hematology Annual Meeting, December 1994.
14. Bazarbashi S, Raja M A, Abdel Warith A, Ezzat A : Controversies in Stage I and II Hodgkin's
Disease - King Faisal Specialist Hospital & Research Centre Experience. Proceedings of Saudi
Oncology Symposium, September 1994.
15. Ezzat A, Raja M A, Wierzbicki R, Bazarbashi S, Abdel Warith A, Khalifa F, Rhydderch D,
Beleno J : Impact of pregnancy on Breast Cancer - A Retrospective Case Control Study. 19th
European Society of Medical Oncology (ESMO) Congress, November 1994.
16. Raja M A, Bazarbashi S, Ezzat A, Abdel Warith A : Novel use of G-CSF to avoid delay in
standard dose chemotherapy in solid tumours. First Oncology Symposium in Jeddah, January 1995.
17. Ezzat A, Raja M A, Berry J, Bazarbashi S, Abdel-Warith A : Gastrointestinal Non Hodgkin's
Lymphoma at KFSH & RC (1985-1992). First Oncology Symposium in Jeddah, January 1995.
18. Ezzat A, Berry J, Jamshed A, Zwaan F, Martin J, Rostom A, Raja M A, Khafaga Y : Early
stage aggressive non-Hodgkin’s lymphoma (NHL) at King Faisal Specialist Hospital and Research
Centre. Saudi Oncology Symposium, Riyadh, Saudi Arabia, 1995.
19. Berry J, Ezzat A, Abdel Warith A, Raja M A, Bazarbashi S : Sequential Taxol/Platinum pilot
study in metastatic breast cancer. Program/Proceedings of The American Society of Clinical
Oncology (ASCO) 31st Annual Meeting, May 1995.
20. Bazarbashi S, Kandil A, Abdel-Warith A, Ezzat A, Berry J, Raja M A, DeVol E, Rhydderch D
: Prognostic Factors in Early Stage Hodgkin's Disease - A Retrospective Analysis of 10 years
Experience. Program/Proceedings of The American Society of Clinical Oncology (ASCO) 31st
Annual Meeting, May 1995.
21. Bazarbashi S, El-Warith A, Ezzat A, Berry J, Raja M A : Alternating ESAP with IMC - An
effective third line non-cross resistant chemotherapy for patients with relapsed Hodgkin's Disease.
Program/Proceedings of The American Society of Clinical Oncology (ASCO) 31st Annual Meeting,
May 1995.
22. Ezzat A, Berry J, Jamshed A, Zwaan F, Martin J, Rostom A, Raja M A, Khafaga Y : Early
Stage Aggressive Non Hodgkin's Lymphoma at KFSH. Proceedings of Current Concepts in
Surgical Pathology, November 1995.
23. Ezzat A, Berry J, Jamshed A, Zwaan F, Martin J, Rostom A, Raja M A, Khafaga Y : Stage I
and II Aggressive Non Hodgkin's Lymphomas - The Predictive Value of the International
Prognostic Index. Program/Proceedings of The American Society of Clinical Oncology (ASCO)
32nd Annual Meeting, May 1996.
24. Ezzat A, Raja M A, Zwaan F, Rostom A, Bazarbashi S : Impact of Pregnancy on non metastatic
Breast Cancer. 3rd Saudi Oncology Symposium, October 1996.
25. Ezzat A, Berry J, Bazarbashi S, Rahal M, Abdel-Warith A, Raja M A, Hanusiewicz D, Cruz A
: Paclitaxel (Taxol) and Cisplatinum - Effective therapy in metastatic Breast Cancer. 3rd Saudi
Oncology Symposium, October 1996.
26. Ezzat A, El Warith A, Bazarbashi S, Rahal M, Raja M A, Pai S, Hanusiewicz D, Ramierez C :
Improved response rate in metastatic breast cancer to the liver by adding antiangiogenic agents to
standard chemotherapy. 3rd Saudi Oncology Symposium, October 1996.
27. Ezzat A, Berry J, Bazarbashi S, Rahal M, Abdel-Warith A, Raja M A, Ramirez C :
Antiangiogenic agents - doxycycline, calcitriol combined with 5 FU, Adriamycin and
Cyclophosphamide (FAC) as first line chemotherapy in metastatic breast cancer to liver. 21st
European Society of Medical Oncology (ESMO) Congress, November 1996.
28. Bazarbashi S, Khafaga Y, El-Warith A, Manji M, Jamshed A, Raja M A, Ezzat A : Epidermoid
cancer of anal canal - treatment results and prognostic variables in 32 cases. 21st European Society
of Medical Oncology (ESMO) Congress, November 1996.
27. Ezzat A, Raja M A, Rostom A, Zwaan F, Akhtar M, Bazarbashi S, Ingemansson S, Jamshed A
: An Overview of Breast Cancer. Proceedings of The 13th Asia Pacific Cancer Conference,
Malaysia, November 1996.
28. Berry J, Ezzat A, Raja M A, Warith A : Taxol/Platinum Phase II study in Metastatic Breast
Cancer. The 10th Scientific Congress of the Kuwait Medical Association, December 1996.
29. Abd-El Warith A, Kofide A, Wierzbicki R, Raja M A, Bazarbashi S, Ezzat A : Prognostic
factors in non-metastatic extremity osteosarcoma (NEOS) treated with adriamycin / cisplatin
neoadjuvant / adjuvant chemotherapy. Program/Proceedings of the American Society of Clinical
Oncology (ASCO) 33rd Annual meeting, May 1997.
30. Bazarbashi S, Kattan S, Lindstedt E, Peracha A, Kardar A, Merdad T, Aslam M, Raja M A,
Rahal M, Pai C, Ezzat A, Hanash K : Phase II Trial of intravesical instillation of Bacillus Calmette
Guerin (BCG) and Interferon Alpha 2B (IFN) on alternate weeks in the Prevention and Treatment of
Superficial Transitional Cell Carcinoma (TCC) of the Urinary Bladder. Program/Proceedings of the
American Society of Clinical Oncology (ASCO) 34th Annual Meeting, May 1998.
31. Bazarbashi S, Pai C, Rahal M, Raja M A, Ezzat A : Phase II Study of Cisplatinum, 5
Fluorouracil and Interferon 2B in Advanced/Metastatic Epidermoid Esophageal Carcinoma.
Program/Proceedings of the American Society of Clinical Oncology (ASCO) 34th Annual Meeting
1998.
32. Ezzat A, Rahal M, Raja M A, Ranginwala M, Bazarbashi S : Pathologic response to Paclitaxel-
Cisplatin versus 5 Fluorouracil, Doxorubicin, Cyclophosphamide primary chemotherapy in Locally
Advanced Breast Cancer (LABC). Program/Proceedings of the American Society of Clinical
Oncology (ASCO) 34th Annual Meeting 1998.
33. Raja M A, Ezzat A, Zwaan F, Bakri Y, Bazarbashi S : Review of Management and Prognosis
in Malignant Ovarian Germ Cell Tumors (OGCT) - A Retrospective Review from a single centre
experience. Program/Proceedings of the American Society of Clinical Oncology (ASCO) 34th
Annual Meeting 1998.
34. Rahal M, Ezzat A, Berry J, Raja M A, Bazarbashi S, Stuart R K, Ajarim D, Ibrahim E : Chronic
administration of Etoposide (VP16) followed by CNOP (Cyclophosphamide, Novantrone, Oncovin,
Prednisone) in elderly patients with aggressive Non-Hodgkins Lymphoma. Program/Proceedings of
the American Society of Clinical Oncology Annual Meeting (ASCO) 35th Annual Meeting 1999.
35. Bazarbashi S, Raja M A, Ezzat A, Kattan S, Lindstedt E, Peracha A, Kardar A H, Merdad T,
Pai C, Rahal M, Al-Sayed A, Ibrahim E, Hanash K : Prospective Phase II Trial of alternating
intravesical BCG and Interferon α-2b (IFN) in Superficial Transitional Cell Carcinoma (TCC) of
the urinary bladder. Program/Proceedings of the American Society of Clinical Oncology (ASCO)
35th Annual Meeting 1999.
36. Stuart R, Ezzat A, Ibrahim E, Ranginwala M, Ajarim D, El-Foudeh M, Raja M A, Bazarbashi
S, Rahal M : CHOP vs. CHOP + Tamoxifen in the management of aggressive Non-Hodgkin's
Lymphoma - Interim analysis of a prospective randomised trial. Program/Proceedings of American
Society of Clinical Oncology Annual Meeting (ASCO) 35th Annual Meeting 1999.
37. Ibrahim E M, Ezzat A A, Stuart R K, Ajarim D, Raja M A : Stage III Breast Cancer - Single
institution experience. Program/Proceedings of the American Society of Clinical Oncology (ASCO)
35th Annual Meeting 1999.
38. Raja M A, Ezzat A A, Ibrahim E, Bazarbashi S, Rahal M, Stuart R K : Prospective comparitive
study of 5HT-3 antagonists in moderately emetogenic chemotherapy. Program/Proceedings of the
American Society of Clinical Oncology (ASCO) 35th Annual Meeting 1999.
39. Rahal M, Bazarbashi S, El Weshi A, Raja M A, Pai C, El Foudeh M, Al Sayed A, Ezzat A,
Ajarim D, Ibrahim E : Salvage chemotherapy for Hodgkin's disease - a seven drug regime with and
without stem cell transplant. 10th European Cancer Congress, September 1999.
40. Ezzat A, Ibrahim E, Ajarim D, Rahal M, Stuart R K, Tulbah A M, Raja M A : A Phase II trial
of neoadjuvant Paclitaxel-Cisplatin in locally advanced breast cancer. European School of
Oncology 1st Milan Breast Cancer Conference, June 1999.
41. Raja M A, Ezzat A A, Ibrahim E, Ajarim D, Bazarbashi S, Stuart R K : Trends in Lymphoma
Presentation – A comparitive analysis between USA and Saudi Arabia. ASCO Pan Arab Conference
on Malignant Lymphoma, November 1999.
42. Bazarbashi S, Rahal M, Raja M A, El Foudeh M, El Weshi A, Ezzat A, Ajarim D, Ibrahim E :
Conventional versus High Dose Chemotherapy (HDC) followed by hematopoietic stem cell
transplantation (HSCT) for relapsed or refractory Hodgkin’s Disease. Program/Proceedings of
American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May 2000.
43. Rahal M, Bazarbashi S, Kandil A, Raja M A, Pai C, Ezzat A : Combined Modality treatment of
early stage supradiaphragmatic Hodgkin’s disease (HD) : A preliminary analysis.
Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May
2000.
44. Memon M, El Weshi A, Bazarbashi S, Ezzat A, Ibrahim E, Rahal M, Raja M A :
Etoposide/Ifosfamide/Cisplatin (VIP) in the treatment of Ewing’s Sarcoma unresponsive to standard
therapy. American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May 2000 – accepted
as poster presentation.
45. El Weshi A, Ibrahim E, Ezzat A, Khafaga Y, Raja M A, Bazarbashi S, Ajarim D : Localised
primary Nasopharyngeal Non-Hodgkin’s Lymphoma (PNP-NHL) : Single centre experience with
47 patients. Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual
Meeting, May 2000.
46. Ibrahim E, Ezzat A, Raja M A, Rahal M, Ajarim D, Mann B, Baloush A, Stuart R, Bazarbashi
S : Primary large B cell gastric (LBCL) non-Hodgkin’s lymphoma – Analysis of 185 patients.
Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May
2000.
47. Ezzat A A, Ibrahim E M, Ajarim D S, Rahal M M, Raja M A, Stuart R K, Tulbah A M, Kandil
A, Al-Malik O A, Bazarbashi S M : High complete pathological response in locally advanced breast
cancer using Paclitaxel and Cisplatin. 23rd Annual San Antonio Breast Cancer Symposium,
December 2000.
48. Rahal M M, Ezzat A A, Ibrahim E M, Ajarim D S, Raja M A, Stuart R K, Tulbah A M, Kandil
A, Bazarbashi S M : Neoadjuvant high-dose sequential chemotherapy with Adriamycin (A),
Paclitaxel (P), and Cyclophosphamide (C) is feasible and effective in poor prognostic patients with
locally advanced breast cancer (LABC). 23rd Annual San Antonio Breast Cancer Symposium,
December 2000.
49. Bazarbashi S, Raja M A, Rahal M, El Weshi A, Pai C, El Foudeh M, Kerr I, Memon M, Ajarim
D, Ezzat A, Stuart R : High Response Rate to Combination Cisplatin, 5-Fluorouracil and Interferon
Alpha in the Treatment of Advanced Esophageal Carcinoma: a Confirmatory Phase II Trial.
Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May
2001 – poster presentation.
50. Al-Amro A, Memon M, Al-Rajhi N, Radwi A, Raja M A, Ezzat A : Chemoradiotherapy in
Patients with Advanced Nasopharyngeal Carcinoma - Single Institution Experience.
Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May
2001.
51. El Weshi A, Ajarim D, Bazarbashi S, Raja M A, Rahal M, El Foudeh M, El Husseiny G,
Memon M, Stuart R, Ezzat A : T-Cell-Rich B-Cell Lymphoma (TCRBCL): Presentation and
Treatment Outcome. Single Center Experience with 29 Patients. Program/Proceedings of American
Society of Clinical Oncology (ASCO) 36th Annual Meeting, May 2001 – poster presentation.
52. Raja M A, Kerr I, El Weshi A, Rahal M, El Foudeh M, Memon M, Subhi J, Bazarbashi S,
Ezzat A : Invasive Mole (IM) and Choriocarcinoma (CC): Prognostic Features, Staging, Survival
and Therapeutic Implications – Single Institution Experience. Program/Proceedings of American
Society of Clinical Oncology (ASCO) 36th Annual Meeting, May 2001.
53. Ajarim D, El Foudeh M, Khafaga Y, Bajouda A, Ezzat A, Ibrahim E, Bazarbashi S, Raja M A,
Rahal M, Pai C, El Weshi A, Baloush A : Primary Non-Hodgkin’s Lymphoma of Bone in Adults.
Program/Proceedings of American Society of Clinical Oncology (ASCO) 36th Annual Meeting, May
2001.
54. El Foudeh M, Memon M, Ezzat A, Younge D, Raja M A, Rahal M, Pai C, El Weshi A, Belal
A, Bajouda A, Abudo A, Tillman R, Spooner D, Carter S, Grimer G : Local Therapy for Ewing’s
Sarcoma of the Pelvis in Adults - Surgery Versus Radiotherapy. Program/Proceedings of American
Society of Clinical Oncology (ASCO) 36th Annual Meeting, May 2001 – poster presentation.
55. Bazarbashi S, Pai C, Raja M A, Rahal M, Ezzat A : Phase II trial of Cisplatin, 5-Fluorouracil
and Interferon 2b in the treatment of advanced urothelial cancer. Poster presentation at Twelfth
International Congress on Cancer Chemotherapy, Paris, February 2002.
56. El Foudeh M, Ezzat A, Bazarbashi S, Al Jurf M, Raja M A, Kandil A, Rahal M, Pai C, El
Weshi A, Al Mutawa N, Bajouda A, Ajarim D : Primary hepatic lymphoma, single institution
experience. Program/Proceedings of American Society of Clinical Oncology (ASCO) 37th Annual
Meeting, May 2002.
57. Rahal M, Memon M, Schultz H, Raja M A, El Weshi A, El Foudeh M, Bazarbashi S, Pai S,
Allam, A, El Kattan K, Ezzat A : Non metastatic chest wall Ewing’s sarcoma family tumour
(ESFT) in adults : A subgroup with favourable outcome. Poster presentation –
Program/Proceedings of American Society of Clinical Oncology (ASCO) 37th Annual Meeting, May
2002.
58. Mourad W A, El Weshi A, El Hosseiny G, Ibrahim E M, Ezzat A, Bazarbashi S, Ajarim D,
Raja M A : The value of the WHO classification and phenotyping in predicting the behaviour of
nasopharyngeal lymphomas. Program/Proceedings of 8th International Conference on Malignant
Lymphoma (Annals of Oncology Vol 13, Suppl 2, abst 442), Lugano, June 2002.
59. Bazarbashi S, Raja M A, Amin T, et al. : Preliminary result of neoadjuvant chemotherapy with
cisplatin, 5-fluorouracil and interferon-2B in operable squamous cell carcinoma of the esophagus :
Poster presentation - A phase II trial. 14th International Congress on Anti-Cancer Treatment, Paris,
February 2003.
60. Raja M A, Al Sayed A, Mourad W, Al Hassan I, Ajarim D, Ezzat A, Bazarbashi S, Meshari K,
Al Shaibani K : Post Transplant Lymphoproliferative Disease (PTLD) : Clinical presentation and
outcome. Poster Presentation - International Congress of Hematological Malignancies, Vancouver,
Canada, February 2003.
61. Raja M A, Ezzat A, Al Shabanah M, Al malik O, Te O, Al Eid H for Breast Cancer Group : 25
years of Breast Cancer experience, Saudi Arabia. Oral presentation – 2nd SAARC Conference on
Clinial Oncology, Kathmandu, Nepal, March 2003.
62. Ezzat A, Rahal M, Ajarim D, Ibrahim E, Bazarbashi S, Raja M A, El Weshi A, El Foudeh M :
Dose dense neoadjuvant sequential chemotherapy in the management of locally advanced breast
cancer : a phase II study. Program/Proceedings of the American Society of Clinical Oncology 39th
Annual Meeting, May 2003.
63. Rahal M, Ibrahim E, Ajarim D, Al Shabanah M, Sorbris R, Bazarbashi S, Al Malik O, Tulbah
A, Raja M A, Ezzat A : Primary systemic chemotherapy with paclitaxel (P) and cisplatin (C ) in
locally advanced breast cancer (LABC) : A safe and effective combination. Program/Proceedings
of the American Society of Clinical Oncology 39th Annual Meeting (abst 202), May 2003.
64. Raja M A, Memon M, El Weshi A, Rahal M, Bazarbashi S, Schultz H, Younge D, Ezzat A :
Feasibility of out-patient chemotherapy for osteosarcoma. Poster presentation -
Program/Proceedings of the American Society of Clinical Oncology 39th Annual Meeting, May
2003.
65. El Weshi A, Memon M, Raja M A, Bazarbashi S, Rahal M, Allam A, Younge D, Ezzat A :
Extraskeletal Ewing’s family of tumors in adults : Presentation, treatment results, and prognostic
factors. Single centre experience with 35 cases. Poster presentation - Program/Proceedings of the
American Society of Clinical Oncology 39th Annual Meeting, May 2003.
66. Bazarbashi S, Raja M A, Amin T, Ezzat A, Pai C, Ajarim D, Rahal M, Memon M, El Foudeh
M, El Weshi A. Neoadjuvant chemotherapy with cisplatin, 5-fluorouracil and interferon alpha-2b in
operable squamous cell carcinoma of the esophagus : A phase II trial. Program/Proceedings of the
American Society of Clinical Oncology 39th Annual Meeting, May 2003.
67. Bazarbashi S, Raja M A, Kattan S, Rahal M, El Weshi A, Pai C, Rehman K, Aslam M, Othman
K, Hanash K: Preliminary reults of Phase II trial of concomitanr administration of intravesical
reduced dose Bacillus Calmette-Guerin (BCG) and interferon α2B (IFN) in the prevention of
recurrence of superficial bladder cancer. Program/Proceedings of the American Society of Clinical
Oncology 40th Annual Meeting, June 2004.
68. Manji M, Raja M A, Kerr I, Badawi I: Concurrent chemoradiation therapy (CCRT) with weekly
cisplatin in locally advanced cancer cervix (LACC): Single institution experience.
Program/Proceedings of the American Society of Clinical Oncology 40th Annual Meeting, June
2004.
69. Ajarim D, Ezzat A, Bazarbashi S, Rahal M, El Foudeh M, Pai C, Raja M A: Gemcitabine plus
cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC).
Program/Proceedings of the American Society of Clinical Oncology 40th Annual Meeting, June
2004.
70. Memon M, Raja M A, Moreau P, Allam A: Outpatient chemotherapy for non-metastatic
Ewing’s sarcoma: Pilot experience. Sarcoma Group, KFSH&RC. Program/Proceedings of the
American Society of Clinical Oncology 40th Annual Meeting, June 2004.
71. Raja M A, Akhtar S, El Weshi A, Maghfoor I: Extra-pulmonary Small Cell Carcinoma
(EPSCC) King Faisal Cancer Center, Riyadh, Saudi Arabia. Program/Proceedings of the American
Society of Clinical Oncology 40th Annual Meeting, June 2004.
72. Raja M A, Bazarbashi S, Tweigieri T: Prospective utilization of clinical pathways to analyse
management of febrile neutropenia in adult solid tumours. 29th European Society of Medical
Oncology (ESMO) Congress, November 2004.
73. Memon M, Raja M A, Allam A, Moreau P, El Weshi A, Ahmed J, Rahal M: Outpatient
chemotherapy for advanced Ewing’s sarcoma (ES): A pilot experience. Poster Presentation - 29th
European Society of Medical Oncology (ESMO) Congress, November 2004.
Participation at Meetings :
1. Third International Symposium on Advances in Urologic Oncology. San Remo, Italy, March
1991.
2. GM-CSF Review Meeting. Miami, USA, December 1991.
3. British Association for Cancer Research / Association of Cancer Physicians / British Oncological
Association Joint Winter Meeting. London, United Kingdom, December 1992.
4. British Oncological Association / Nordic Cancer Societies. Canterbury, United Kingdom, July
1992.
5. Riyadh Oncology Symposium. Saudi Arabia, April 1993.
6. Fifth International Conference on Malignant Lymphoma. Lugano, Switzerland, June 1993.
7. American Society of Clinical Oncology (ASCO) 31st Annual Meeting. Los Angeles, USA, May
1995.
8. 3rd Saudi Oncology Symposium. Riyadh, Saudi Arabia, October 1996.
9. 21st European Society of Medical Oncology (ESMO) Congress. Vienna, Austria, November
1996.
10. 9th European Cancer Conference (ECCO). Hamburg, Germany, September 1997.
11. 17th International Cancer Congress (UICC). Rio de Janeiro, Brazil, August 1998.
12. 23rd European Society of Medical Oncology (ESMO) Congress. Athens, Greece, November
1998.
13. Modern Management of Advanced Cancer : How to help your patients – European School of
Oncology Workshop, Riyadh, KSA, October 1999.
14. ASCO – Pan Arab Conference on Malignant Lymphoma, Cairo, Egypt, November 1999.
15. XV Asia Pacific Cancer Congress, Chennai, India, December 1999.
16. 36th American Society of Clinical Oncology (ASCO) Annual Meeting, New Orleans, USA, May
2000.
17. International symposium on New Trends in the Management of Lymphoma, Kuwait, November
2000.
18. The 4th U.A.E. International Cancer Conference, Abu Dhabi, U.A.E., January 2001.
19. 12th International Meeting of European Society of Gynaecological Oncology, Venice, Italy,
May 2001.
20. 38th American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA, May
2002.
21. 25th Annual Breast Cancer International Symposium, San Antonio, Texas, USA, December
2002.
22. 2nd SAARC Conference on Clinial Oncology, Kathmandu, Nepal, March 2003
23. 12th European Cancer Conference (ECCO) Copenhagen, Denmark, October 2003.
24. Delivered lecture on “Management of Cancer Prostate” Urology Department Government
General Hospital, Chennai India 4 August 2004.
25. Delivered lecture on “Screening for Cancer” to Pondicherry Association of General
Practitioners, Pondicherry, India, 29 August 2004.
26. Symposium on Adjuvant Systemic Therapy in Breast Cancer, Tata Memorial Hospital, Mumbai,
India, November 2004.
27. Chairman, symposium on Skin Cancer, SRMC Chennai, India, november 2004.
28. Bombay Conference on Lung Cancer Update, India, February 2005.
29. Delivered lecture on “Chemotherapy in Head & Neck Cancer, SRMC Chennai, India, February
2005.
30. Delivered lecture on “Medical Management of Colorectal Cancer” SRMC Chennai, India, April
2005.
31. Delivered lecture on “Medical Management of Cervix Cancer” to IMA, NAM Branch, Chennai,
India, July 2005.
32. Delivered lecture on “Extending Horizon in Treatment of Cancer in Women” meeting of
Bangalore Society of Obstetrics & Gynaecology, Bangalore, India, August 2005.
33. ECCO 13 – European Cancer Care Organisations Annual Conference, Paris France, October
2005.
34. Chairman, Symposium on Supportive Care in Cancer, Chennai, India, November 2005.
35. International Update on Myeloma and 2004 ASH Meeting, Mumbai, India, January 2006.
36. 10th National Conference of Breast Cancer Foundation of India, Hyderabad, March 2006.
37. UICC World Cancer Congress, Washington, USA, July 2006.
38. 7th International Meeting of Asian Society of Clinical Oncology, Beijing, China, September
2006.
39. 31st Annual Meeting of European Society of Medical Oncology (ESMO), Istanbul, Turkey,
September 2006.
40. 29th Annual San Antonio Breast Cancer Symposium, San Antonio Texas, USA, December
2006.
41. Chairperson, Symposium on Peritoneal Surgery / Intraperitoneal Chemotherapy, Chennai, India,
January 2007.
42. Delivered lecture on “Adjuvant Chemotherapy in Breast Cancer” at Association of Radiation
Oncologists of India (AROI) meeting, Chennai, India, March 2007.
43. Best of ASCO Meeting, San Francisco, USA, July 2007.
44. 1st KL International Breast and Colorectal Cancer Congress, Kuala Lumpur, Malaysia, August
2007.
45. European Cancer Care Organizations (ECCO) Meeting, Barcelona, Spain, September 2007.
46. First Asian Breast Cancer Congress, New Delhi, India, February 2008
47. 33rd Annual meeting of European Society of Medical Oncology (ESMO), Stockholm, Sweden
September 2008
48. Organising Secretary, Indian Society of Oncology / Indian Society of Medical & Paediatric
Oncology Biennial National Meeting, Chennai 13-15 February, 2009.
49. 7th International Symposium of Targeted Anticancer Therapies, Amsterdam, 23-25 March
2009.
50. Asian Oncology Summit, Singapore, 3-5 April 2009.
51. 13th World Conference on Lung Cancer, San Francisco, 31July – 4 August, 2009.
52. 35th European Society of Medical Oncology Congress, Milan, 8-12 October 2010.
53. 28th Chemotherapy Foundation Symposium, New York, 9-13 November, 2010.
54. 5th ISC International Conference and 1st GOCCI International Conference on Cancer
Therapeutics - Molecular Targets, Pharmacology and Clinical Applications "Focus on
Gastrointestinal Tract Oncology", Florence Italy, 3-5 March 2011.
55. American Society of Clinical Oncology, Chicago USA, 1-5 June 2011.
56. 3rd Trends in Head & Neck Cancer Meeting, Rome Italy, 3-5 November 2011.
Other:
Lectures / Chairmanship in various local, regional, national conferenes
Multiple Television and radio shows
Teaching MBBS students, various post-graduate students, DNB students, nurses
Memberships :
1. American Society of Clinical Oncology
2. European Society of Medical Oncology
3. European School of Oncology
4. European Association of Cancer Research
5. Association of Physicians of India
6. Royal Society of Medicine, United Kingdom
7. Indian Society of Medical & Paediatric Oncology
Hobbies : Reading
Writing poems
Travelling
Philately
Crosswords
